
<!DOCTYPE html>
<!--[if lt IE 7]>      <html class="no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]-->
<!--[if IE 7]>         <html class="no-js lt-ie9 lt-ie8"> <![endif]-->
<!--[if IE 8]>         <html class="no-js lt-ie9"> <![endif]-->
<!--[if gt IE 8]><!--> <html class="no-js"> <!--<![endif]-->
	<head>
	<meta charset="utf-8">
	<meta http-equiv="X-UA-Compatible" content="IE=edge">
	<title>CÁNCER DE MAMA</title>
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<meta name="description" content="CÁNCER DE MAMA" />
	<meta name="keywords" content="oncologia, cancer mama, medicina" />
	<meta name="author" content="e-oncologia" />

  <!--
	//////////////////////////////////////////////////////


	//////////////////////////////////////////////////////
	-->
	<link rel="shortcut icon" type="image/png" href="images/logo.png"/>

	<link href='https://fonts.googleapis.com/css?family=Roboto:400,300,600,400italic,700' rel='stylesheet' type='text/css'>
	<link href='https://fonts.googleapis.com/css?family=Montserrat:400,700' rel='stylesheet' type='text/css'>

	<!-- Animate.css -->
	<link rel="stylesheet" href="css/animate.css">
	<!-- Icomoon Icon Fonts-->
	<link rel="stylesheet" href="css/icomoon.css">
	<!-- Bootstrap  -->
	<link rel="stylesheet" href="css/bootstrap.css">
	<!-- Owl Carousel -->
	<link rel="stylesheet" href="css/owl.carousel.min.css">
	<link rel="stylesheet" href="css/owl.theme.default.min.css">
	<!-- Theme style  -->
	<link rel="stylesheet" href="css/style.css">

	<!-- Modernizr JS -->
	<script src="js/modernizr-2.6.2.min.js"></script>
	<!-- FOR IE9 below -->
	<!--[if lt IE 9]>
	<script src="js/respond.min.js"></script>
	<![endif]-->
	</head>

	<body>

	<div id="ico-page">
		<a href="#" class="js-ico-nav-toggle ico-nav-toggle"><i></i></a>
		<aside id="ico-aside" role="complementary" class="border js-fullheight" style="background-image: url(images/BGoscuro.jpg);">
			<h3 id="ico-logo"><a href="index.html"><img src="images/logo.png" alt="Cáncer de Mama" height="120"></a></h3>
			<nav id="ico-main-menu" role="navigation">
				<ul>
					<li><a href="m1u1.html">MÓDULO 1</a></li>
					<ol>
						<li><a href="m1u1.html">Epidemiología</a></li>
						<li><a href="m1u2.html">Estrategias preventivas y de cribado</a></li>
						<li><a href="m1u3.html">Carcinoma in situ</a></li>
						<li><a href="m1u3c1a.html"><span class="bgrosa">CASO CLÍNICO 1</span></a></li>
						<li><a href="m1u4.html">Biología del cáncer de mama</a></li>
						<li><a href="m1u5.html">Fundamentos del cáncer de mama hereditario</a></li>
						<li><a href="m1u5cc2.html"><span class="bgrosa">CASO CLÍNICO 2</span></a></li>
					</ol>
					<br>
					<li><a href="m2u1.html">MÓDULO 2</a></li>
					<ol>
						<li><a href="m2u1.html">Diagnóstico del cáncer de mama</a></li>
						<li><a href="m2u2.html">Patrones clínicos de presentación</a></li>
						<li><a href="m2u3.html">Factores pronósticos y predictivos</a></li>
						<li><a href="m2u3cc3.html"><span class="bgrosa">CASO CLÍNICO 3</span></a></li>
						<li><a href="m2u4.html">Tratamiento loco-regional</a></li>
						<li><a href="m2u5.html">Tratamiento sistémico</a></li>
							<ol>
								<li><a href="m2u5a.html"><span class="negritaDorado">· </span>Principios del modelo NA</a></li>
								<li><a href="m2u5b.html"><span class="negritaDorado">· </span>Trat. (neo)adyuvante de la enfermedad luminal</a></li>
								<li><a href="m2u5c.html"><span class="bgrosa">CASO CLÍNICO 4 & 5</span></a></li>
								<li><a href="m2u5d.html"><span class="negritaDorado">· </span>Trat. (neo)adyuvante de la enfermedad HER2+</a></li>
								<li><a href="m2u5e.html"><span class="bgrosa">CASO CLÍNICO 6 & 7</span></a></li>
								<li><a href="m2u5f.html"><span class="negritaDorado">· </span>Trat. (neo)adyuvante de la enfermedad TN</a></li>
								<li><a href="m2u5g.html"><span class="bgrosa">CASO CLÍNICO 8 & 9</span></a></li>
							</ol>
					</ol>
					<br>
					<li><a href="m3u1.html">MÓDULO 3</a></li>
					<ol>
						<li><a href="m3u1.html">Diagnóstico de la enfermedad diseminada</a></li>
						<li><a href="m3u2.html">Recaída locorregional</a></li>
						<li><a href="m3u3.html">Tratamiento sistémico anti-tumoral</a></li>
						<ol>
							<li><a href="m3u3a.html"><span class="negritaDorado">· </span>Principios del modelo NA</a></li>
							<li><a href="m3u3b.html"><span class="negritaDorado">· </span>Trat. de la enfermedad luminal diseminada</a></li>
							<li><a href="m3u3c.html"><span class="bgrosa">CASO CLÍNICO 10 & 11</span></a></li>
							<li><a href="m3u3d.html"><span class="negritaDorado">· </span>Trat. de la enfermedad HER2+ diseminada</a></li>
							<li><a href="m3u3e.html"><span class="bgrosa">CASO CLÍNICO 12 & 13</span></a></li>
							<li><a href="m3u3f.html"><span class="negritaDorado">· </span>Trat. de la enfermedad TN</a></li>
							<li><a href="m3u3g.html"><span class="bgrosa">CASO CLÍNICO 14</span></a></li>
						</ol>
						<li><a href="m3u4.html">Monitorización y seguimiento</a></li>
						<li><a href="m3u5.html">Papel del tratamiento local en la enfermedad diseminada</a></li>
						<li><a href="m3u6.html">Manejo de la enfermedad en virtud de su localización</a></li>
						<li><a href="m3u6cc15.html"><span class="bgrosa">CASO CLÍNICO 15</span></a></li>
						<li><a href="m3u7.html">Escenarios específicos en cáncer de mama</a></li>
					</ol>
				</ul>
			</nav>
			<div>
					<br>
					<img src="images/LOGOeonco.png" alt="" width="120" class="centrada"><br>
					<img src="images/LOGOseom.png" alt="" width="120" class="centrada"><br>
			</div>
		</aside>


		<div id="ico-main">

			<div class="ico-franja">
				<div class="ico-narrow-content animate-box">
							<h2>MÓDULO 1 <span class="doradoActivo">:</span> EPIDEMIOLOGÍA, BIOLOGÍA & ENFERMEDAD PRE-INVASIVA</h2>
				</div>
			</div>






			<div class="ico-narrow-content">
				 <div class="row animate-box" data-animate-effect="fadeInLeft">
					<div class="col-md-12">
					<h3>1<span class="dorado">.</span>5 Fundamentos del cáncer de mama hereditario</h3>
			</div>
			</div>
		</div>




		<div class="ico-narrow-content">
			 <div class="row animate-box" data-animate-effect="fadeInLeft">
				<div class="col-md-12">
					<h2 class="bgdorado">&nbspObjetivos&nbsp</h2>
				</div>
			</div>
	</div>
		<div class="ico-narrow-content">
				<div class="row animate-box" data-animate-effect="fadeInLeft">
						<div class="row">
							<div class="col-md-12">

							<div class="col-md-3">
								<img src="images/hereditario.png" alt="" class="img-responsive centrada">
								<p>Conocer la epidemiología del cáncer de mama hereditario.</p>
							</div>
							<div class="col-md-3">
								<img src="images/adn.png" alt="" class="img-responsive centrada">
								<p>Conocer los principales genes cuyas mutaciones predisponen a cáncer de mama.</p>
							</div>
							<div class="col-md-3">
								<img src="images/documento.png" alt="" class="img-responsive centrada">
								<p>Manejar los conceptos básicos de consejo genético oncológico.</p>
							</div>
							<div class="col-md-3">
								<img src="images/lupa.png" alt="" class="img-responsive centrada">
								<p>Aprender las opciones de disminución de riesgo y diagnóstico precoz en pacientes portadoras de mutaciones en BRCA1 y 2.</p>
							</div>
							<div class="col-md-12">
								<p>Dado que en otros módulos de este tema se hablará extensamente de tratamientos sistémicos, no será objeto de esta unidad hablar de los mismos.</p>
							</div>
							</div>
						</div>
					</div>
				</div>


			<div class="ico-narrow-content">
				 <div class="row animate-box" data-animate-effect="fadeInLeft">
					<div class="col-md-12">
						<h2 class="bgdorado">&nbspEpidemiología y Bases biológicas &nbsp</h2>
					</div>
				</div>
			</div>

			<div class="ico-franja">
				<div class="ico-narrow-content animate-box">
					 <h6 class="text-center">En España se calcula que 3 de cada 10 pacientes con cáncer de mama tiene al menos un factor de riesgo para ser portadora de una mutación en genes de predisposición hereditaria a cáncer de mama (1)</h6>
				</div>
			</div>

		<div class="ico-narrow-content">
		 <div class="row animate-box" data-animate-effect="fadeInLeft">
			<div class="col-md-12">
				<p>No se disponen de cifras poblacionales de cuántas pacientes con estos criterios, o con los criterios de SEOM (ver más abajo) son portadoras de una mutación patogénica en línea germinal en genes relacionados con cáncer de mama y/u ovario (fundamentalmente BRCA1 y 2). Según nuestras series, aproximadamente 14% de pacientes con criterios de riesgo serían portadoras de mutaciones patogénicas en BRCA1 y 2 (2,3).</p>
				<p>En otros estudios con pacientes con cáncer de mama triple negativo (un subtipo con especial frecuencia de mutaciones) se encontraron entre un 14-17% de mutaciones germinales (cerca de un 5% en genes no BRCA1 ni 2) (4,5)</p>
				<p>Si bien no se dispone de cifras en pacientes con cáncer de mama sin seleccionar por factores de riesgo, se podría asumir que, si 3 de cada 10 pacientes tienen algún factor de riesgo, y que de estas (con las cifras arriba indicadas) 1 de cada 6 tendrían una mutación en genes de predisposición a cáncer hereditario, podríamos estimar que 1 de cada 20 (5%) de pacientes con cáncer de mama tendrían una mutación en estos genes, siendo este porcentaje más alto cuantos más factores de riesgo tengan.</p>
				<p>Las guías SEOM recomiendan la realización de estudio genético en los supuestos recogidos en <span class="rosa italic">la figura 1</span></p>
			</div>
		</div>
	</div>

	<div class="ico-fondo">
		<div class="ico-narrow-content animate-box">
				 <table class="ico-fondotable">
					<tr>
						<th colspan="3"><h4 class="bgrosaBold">Regardless of family history:</h4></th>
					</tr>
						<tr>
							<td><p class="negrita rosa"></p></td>
						</tr>
					<tr>
						 <td><p></p></td>
					 </tr>
					 <tr>
 						 <td><p></p></td>
 					 </tr>
					 <tr>
 						 <td><p></p></td>
 					 </tr>
					 <tr>
 						 <td><p></p></td>
 					 </tr>
					 <tr>
 						 <td><p></p></td>
 					 </tr>
					 <tr>
 						 <td><p></p></td>
 					 </tr>
				 </table>



				</div>
			</div>
		</div>


























				<div class="ico-fondo">
					<div class="ico-narrow-content animate-box">
							 <table class="ico-fondotable">
							 	<tr>
							 		<th  id="biblio" colspan="3"><h4 class="bgrosaBold">Bibliografía</h4></th>
							 	</tr>
							 	<tr>
							 		<td><p class="rosa negrita">1</p></td>
							 		<td><p class="rosa italic"></p></td>
									<td><p>Inman JL, Robertson C, Mott JD, Bissell MJ. Mammary gland development: cell fate specification, stem cells and the microenvironment. Development. 15 de marzo de 2015;142(6):1028-42.</p></td>
							 	</tr>
								<tr>
							 		<td><p class="rosa negrita">2</p></td>
							 		<td><p class="rosa italic"></p></td>
									<td><p>Skibinski A, Kuperwasser C. The origin of breast tumor heterogeneity. Oncogene. octubre de 2015;34(42):5309-16.</p></td>
							 	</tr>
								<tr>
							 		<td><p class="rosa negrita">3</p></td>
							 		<td><p class="rosa italic"></p></td>
									<td><p>Cristea S, Polyak K. Dissecting the mammary gland one cell at a time. Nature Communications. 26 de junio de 2018;9(1):2473. </p></td>
							 	</tr>
								<tr>
							 		<td><p class="rosa negrita">4</p></td>
							 		<td><p class="rosa italic"></p></td>
									<td><p>Cowell CF, Weigelt B, Sakr RA, Ng CKY, Hicks J, King TA, et al. Progression from ductal carcinoma in situ to invasive breast cancer: Revisited. Molecular Oncology. 1 de octubre de 2013;7(5):859-69.</p></td>
							 	</tr>
								<tr>
							 		<td><p class="rosa negrita">5</p></td>
							 		<td><p class="rosa italic"></p></td>
									<td><p>Zhang M, Lee AV, Rosen JM. The Cellular Origin and Evolution of Breast Cancer. Cold Spring Harb Perspect Med. 1 de marzo de 2017;7(3):a027128.</p></td>
							 	</tr>
								<tr>
							 		<td><p class="rosa negrita">6</p></td>
							 		<td><p class="rosa italic"></p></td>
									<td><p>Balani S, Nguyen LV, Eaves CJ. Modeling the process of human tumorigenesis. Nature Communications. 25 de mayo de 2017;8:15422.</p></td>
							 	</tr>
								<tr>
							 		<td><p class="rosa negrita">7</p></td>
							 		<td><p class="rosa italic"></p></td>
									<td><p>Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer. septiembre de 2007;7(9):659-72.</p></td>
							 	</tr>
								<tr>
							 		<td><p class="rosa negrita">8</p></td>
							 		<td><p class="rosa italic"></p></td>
									<td><p>Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 19 de septiembre de 2013;501(7467):346-54.</p></td>
							 	</tr>
								<tr>
							 		<td><p class="rosa negrita">9</p></td>
							 		<td><p class="rosa italic"></p></td>
									<td><p>Bombonati A, Sgroi DC. The Molecular Pathology of Breast Cancer Progression. J Pathol. enero de 2011;223(2):307-17.</p></td>
							 	</tr>
								<tr>
									<td><p class="rosa negrita">10</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Naxerova K, Jain RK. Using tumour phylogenetics to identify the roots of metastasis in humans. Nat Rev Clin Oncol. mayo de 2015;12(5):258-72.</p></td>
								</tr>
								<tr>
							 		<td><p class="rosa negrita">11</p></td>
							 		<td><p class="rosa italic"></p></td>
									<td><p>Obenauf AC, Massagué J. Surviving at a distance: organ specific metastasis. Trends Cancer. 1 de septiembre de 2015;1(1):76-91.</p></td>
							 	</tr>
								<tr>
							 		<td><p class="rosa negrita">12</p></td>
							 		<td><p class="rosa italic"></p></td>
									<td><p>Cejalvo JM, Dueñas EM de, Galván P, García-Recio S, Gasión OB, Paré L, et al. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. Cancer Res. 1 de mayo de 2017;77(9):2213-21.</p></td>
							 	</tr>
								<tr>
							 		<td><p class="rosa negrita">13</p></td>
							 		<td><p class="rosa italic"></p></td>
									<td><p>Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S, Martincorena I, et al. Genomic Evolution of Breast Cancer Metastasis and Relapse. Cancer Cell. 14 de agosto de 2017;32(2):169-184.e7.</p></td>
							 	</tr>
								<tr>
							 		<td><p class="rosa negrita">14</p></td>
							 		<td><p class="rosa italic"></p></td>
									<td><p>Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 17 de agosto de 2000;406(6797):747-52.</p></td>
							 	</tr>
								<tr>
							 		<td><p class="rosa negrita">15</p></td>
							 		<td><p class="rosa italic"></p></td>
									<td><p>Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS. 11 de septiembre de 2001;98(19):10869-74.</p></td>
							 	</tr>
								<tr>
							 		<td><p class="rosa negrita">16</p></td>
							 		<td><p class="rosa italic"></p></td>
									<td><p>Perou CM. Molecular Stratification of Triple-Negative Breast Cancers. The Oncologist. 1 de noviembre de 2010;15(Supplement 5):39-48.</p></td>
							 	</tr>
								<tr>
							 		<td><p class="rosa negrita">17</p></td>
							 		<td><p class="rosa italic"></p></td>
									<td><p>Prat A, Pascual T, Adamo B. Intrinsic molecular subtypes of HER2+ breast cancer. Oncotarget. 4 de septiembre de 2017;8(43):73362-3. </p></td>
							 	</tr>
								<tr>
							 		<td><p class="rosa negrita">18</p></td>
							 		<td><p class="rosa italic"></p></td>
									<td><p>Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Molecular Oncology. 1 de febrero de 2011;5(1):5-23.</p></td>
							 	</tr>
								<tr>
							 		<td><p class="rosa negrita">19</p></td>
							 		<td><p class="rosa italic"></p></td>
									<td><p>Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. The Breast. 1 de noviembre de 2015;24:S26-35.</p></td>
							 	</tr>
								<tr>
									<td><p class="rosa negrita">20</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 1 de agosto de 2017;28(8):1700-12.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">21</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. The Lancet. noviembre de 2011;378(9805):1812-23.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">22</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Hicks J, Krasnitz A, Lakshmi B, Navin NE, Riggs M, Leibu E, et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Research. 2006;16(12):1465-79.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">23</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Morganella S, Alexandrov LB, Glodzik D, Zou X, Davies H, Staaf J, et al. The topography of mutational processes in breast cancer genomes. Nat Commun [Internet]. 2 de mayo de 2016 [citado 29 de septiembre de 2018];7. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5001788/"><span class="rosa icon-external-link"></span></a></p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">24</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Network TCGA. Comprehensive molecular portraits of human breast tumours. Nature. 4 de octubre de 2012;490(7418):61-70.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">25</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, et al. Multi-platform analysis of 12 cancer types reveals molecular classification within and across tissues-of-origin. Cell. 14 de agosto de 2014;158(4):929-44.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">26</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Anderson WF, Rosenberg PS, Prat A, Perou CM, Sherman ME. How Many Etiological Subtypes of Breast Cancer: Two, Three, Four, Or More? J Natl Cancer Inst [Internet]. 9 de agosto de 2014 [citado 29 de septiembre de 2018];106(8). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148600/"><span class="rosa icon-external-link"></span></a></p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">27</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 21 de junio de 2012;486(7403):346-52.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">28</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Russnes HG, Lingjærde OC, Børresen-Dale A-L, Caldas C. Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters. Am J Pathol. octubre de 2017;187(10):2152-62.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">29</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple negative breast cancers. Nature [Internet]. 4 de abril de 2012 [citado 25 de noviembre de 2017];486(7403).<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3863681/"><span class="rosa icon-external-link"></span></a></p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">30</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Pereira B, Chin S-F, Rueda OM, Vollan H-KM, Provenzano E, Bardwell HA, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 10 de 2016;7:11479.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">31</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Stephens PJ, Tarpey PS, Davies H, Loo PV, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 16 de mayo de 2012;486(7403):400-4.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">32</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 02 de 2016;534(7605):47-54.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">33</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 1 de julio de 2011;121(7):2750-67.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">34</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLOS ONE. 16 de junio de 2016;11(6):e0157368.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">35</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua S, et al. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-negative Breast Cancer. Clinical Cancer Research [Internet]. 10 de septiembre de 2014 [citado 24 de enero de 2015]. <a href="http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-14-0432"><span class="rosa icon-external-link"></span></a></p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">36</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Jézéquel P, Loussouarn D, Guérin-Charbonnel C, Campion L, Vanier A, Gouraud W, et al. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Research. 20 de marzo de 2015;17(1):43.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">37</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart M, Rothe F, et al. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Annals of Oncology [Internet]. 22 de enero de 2018 [citado 30 de marzo de 2018]. <a href="https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy024/4819112"><span class="rosa icon-external-link"></span></a></p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">38</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, et al. Genomic Characterization of Primary Invasive Lobular Breast Cancer. Journal of Clinical Oncology. junio de 2016;34(16):1872-81.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">39</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Michaut M, Chin S-F, Majewski I, Severson TM, Bismeijer T, Koning L de, et al. Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Scientific Reports. 5 de enero de 2016;6:18517.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">40</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell. octubre de 2015;163(2):506-19.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">41</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Du T, Zhu L, Levine KM, Tasdemir N, Lee AV, Vignali DAA, et al. Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism. Scientific Reports. 8 de mayo de 2018;8(1):7205.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">42</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Desmedt C, Salgado R, Fornili M, Pruneri G, Van den Eynden G, Zoppoli G, et al. Immune Infiltration in Invasive Lobular Breast Cancer. J Natl Cancer Inst [Internet]. [citado 21 de mayo de 2018]. <a href="https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djx268/4881757"><span class="rosa icon-external-link"></span></a></p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">43</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nature Reviews Cancer. mayo de 2012;12(5):323-34.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">44</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Ng CKY, Schultheis AM, Bidard F-C, Weigelt B, Reis-Filho JS. Breast Cancer Genomics From Microarrays to Massively Parallel Sequencing: Paradigms and New Insights. JNCI: Journal of the National Cancer Institute [Internet]. mayo de 2015 [citado 30 de septiembre de 2018];107(5).<a href="https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djv015"><span class="rosa icon-external-link"></span></a></p></td></p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">45</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C, et al. Toward understanding and exploiting tumor heterogeneity. Nature Medicine. agosto de 2015;21(8):846-53.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">46</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Zardavas D, Irrthum A, Swanton C, Piccart M. Clinical management of breast cancer heterogeneity. Nature Reviews Clinical Oncology. julio de 2015;12(7):381-94.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">47</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Brooks MD, Burness ML, Wicha MS. Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer. Cell Stem Cell. 3 de septiembre de 2015;17(3):260-71.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">48</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Nawaz S, Heindl A, Koelble K, Yuan Y. Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. Modern Pathology. junio de 2015;28(6):766-77.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">49</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Heindl A, Sestak I, Naidoo K, Cuzick J, Dowsett M, Yuan Y. Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer. J Natl Cancer Inst. 1 de febrero de 2018;110(2):166-75.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">50</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. marzo de 2011;144(5):646-74.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">51</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Hanahan D, Coussens LM. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment. Cancer Cell. marzo de 2012;21(3):309-22.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">52</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Zardavas D, Baselga J, Piccart M. Emerging targeted agents in metastatic breast cancer. Nature Reviews Clinical Oncology. 5 de marzo de 2013;10(4):191-210.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">53</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Dai X, Xiang L, Li T, Bai Z. Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. Journal of Cancer. 2016;7(10):1281-94.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">54</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Le Romancer M, Poulard C, Cohen P, Sentis S, Renoir J-M, Corbo L. Cracking the Estrogen Receptor’s Posttranslational Code in Breast Tumors. Endocr Rev. 1 de octubre de 2011;32(5):597-622.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">55</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Osborne CK, Schiff R. Mechanisms of Endocrine Resistance in Breast Cancer. Annual Review of Medicine. 18 de febrero de 2011;62(1):233-47.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">56</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Nardone A, De Angelis C, Trivedi MV, Osborne CK, Schiff R. The Changing Role of ER in Endocrine Resistance. Breast. noviembre de 2015;24(0 2):S60-6.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">57</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Ma CX, Reinert T, Chmielewska I, Ellis MJ. Mechanisms of aromatase inhibitor resistance. Nature Reviews Cancer. 24 de abril de 2015;15(5):261-75.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">58</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Diep CH, Daniel AR, Mauro LJ, Knutson TP, Lange CA. Progesterone action in breast, uterine, and ovarian cancers. J Mol Endocrinol. abril de 2015;54(2):R31-53.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">59</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Hagan CR, Lange CA. Molecular determinants of context-dependent progesterone receptor action in breast cancer. BMC Medicine. 20 de febrero de 2014;12:32.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">60</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Gerratana L, Basile D, Buono G, De Placido S, Giuliano M, Minichillo S, et al. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. Cancer Treatment Reviews. 1 de julio de 2018;68:102-10.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">61</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Basile D, Cinausero M, Iacono D, Pelizzari G, Bonotto M, Vitale MG, et al. Androgen receptor in estrogen receptor positive breast cancer: Beyond expression. Cancer Treatment Reviews. diciembre de 2017;61:15-22.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">62</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer. 12 de 2012;12(8):553-63.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">63</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. julio de 2009;9(7):463-75.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">64</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Escrivá-de-Romaní S, Arumí M, Bellet M, Saura C. HER2-positive breast cancer: Current and new therapeutic strategies. The Breast. 1 de junio de 2018;39:80-8.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">65</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M, et al. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treatment Reviews. diciembre de 2013;39(8):935-46.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">66</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nature Reviews Clinical Oncology. 12 de febrero de 2013;10(3):143-53.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">67</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 9 de febrero de 2012;366(6):520-9.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">68</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer and Metastasis Reviews. diciembre de 2016;35(4):515-24.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">69</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Costa RLB, Han HS, Gradishar WJ. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Research and Treatment [Internet]. 7 de febrero de 2018 [citado 18 de marzo de 2018]. <a href="http://link.springer.com/10.1007/s10549-018-4697-y"><span class="rosa icon-external-link"></span></a></p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">70</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nature Reviews Cancer. marzo de 2009;9(3):153-66.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">71</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Ma CX, Reinert T, Chmielewska I, Ellis MJ. Mechanisms of aromatase inhibitor resistance. Nature Reviews Cancer. 24 de abril de 2015;15(5):261-75.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">72</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Pernas S, Tolaney SM, Winer EP, Goel S. CDK4/6 inhibition in breast cancer: current practice and future directions. Ther Adv Med Oncol [Internet]. 17 de julio de 2018 [citado 30 de septiembre de 2018];10. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050811/"><span class="rosa icon-external-link"></span></a></p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">73</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Banerjee S, Dowsett M, Ashworth A, Martin L-A. Mechanisms of Disease: angiogenesis and the management of breast cancer. Nature Reviews Clinical Oncology. septiembre de 2007;4(9):536-50.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">74</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Aalders KC, Tryfonidis K, Senkus E, Cardoso F. Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives. Cancer Treatment Reviews. 1 de febrero de 2017;53:98-110.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">75</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 17 de 2017;355(6330):1152-8.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">76</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Brown JS, O’Carrigan B, Jackson SP, Yap TA. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. Cancer Discov. 1 de enero de 2017;7(1):20-37.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">77</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee K-H, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. New England Journal of Medicine. 15 de agosto de 2018;0(0):null.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">78</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 10 de 2017;377(6):523-33.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">79</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Pasculli B, Barbano R, Parrella P. Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine. Seminars in Cancer Biology. 1 de agosto de 2018;51:22-35.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">80</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Davalos V, Martinez-Cardus A, Esteller M. The Epigenomic Revolution in Breast Cancer: From Single-Gene to Genome-Wide Next-Generation Approaches. The American Journal of Pathology. 1 de octubre de 2017;187(10):2163-74.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">81</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. septiembre de 2017;14(9):531-48.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">82</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Senft D, Leiserson MDM, Ruppin E, Ronai ZA. Precision Oncology: The Road Ahead. Trends in Molecular Medicine. octubre de 2017;23(10):874-98.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">83</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Yap TA, Lorente D, Omlin A, Olmos D, Bono JS de. Circulating Tumor Cells: A Multifunctional Biomarker. Clin Cancer Res. 15 de mayo de 2014;20(10):2553-68.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">84</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Alix-Panabières C, Pantel K. Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay. Expert Review of Molecular Diagnostics. 2 de noviembre de 2015;15(11):1411-7.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">85</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Alix-Panabières C, Pantel K. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov. 1 de mayo de 2016;6(5):479-91.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">86</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Ramos-Medina R, Moreno F, Lopez-Tarruella S, Del Monte-Millán M, Márquez-Rodas I, Durán E, et al. Review: circulating tumor cells in the practice of breast cancer oncology. Clin Transl Oncol. Diciembre de 2015.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">87</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer. New England Journal of Medicine. 19 de agosto de 2004;351(8):781-91.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">88</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Bidard F-C, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. The Lancet Oncology. abril de 2014;15(4):406-14.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">89</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, et al. Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. Journal of Clinical Oncology. noviembre de 2014;32(31):3483-9.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">90</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Bidard F-C, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, et al. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. J Natl Cancer Inst. 1 de junio de 2018;110(6):560-7.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">91</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, Zwingers T, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 15 de mayo de 2014;106(5).</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">92</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Markou A, Farkona S, Schiza C, Efstathiou T, Kounelis S, Malamos N, et al. PIK3CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer. Clin Cancer Res. 15 de noviembre de 2014;20(22):5823-34.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">93</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>De Mattos-Arruda L, Caldas C. Cell-free circulating tumour DNA as a liquid biopsy in breast cancer. Molecular Oncology. 1 de marzo de 2016;10(3):464-74.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">94</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Dawson S-J, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin S-F, et al. Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. New England Journal of Medicine. 28 de marzo de 2013;368(13):1199-209.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">95</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, et al. Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood. Clin Cancer Res. 15 de junio de 2012;18(12):3462-9.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">96</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Fribbens C, O’Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, et al. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. J Clin Oncol. 1 de septiembre de 2016;34(25):2961-8.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">97</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, et al. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. JAMA Oncol. 1 de octubre de 2016;2(10):1310-5.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">98</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. enero de 2018;19(1):87-100.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">99</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 26 de agosto de 2015;7(302):302ra133.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">100</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol. marzo de 2014;11(3):129-44.</p></td>
								</tr>
								<tr>
									<td><p class="rosa negrita">101</p></td>
									<td><p class="rosa italic"></p></td>
									<td><p>Xu R, Rai A, Chen M, Suwakulsiri W, Greening DW, Simpson RJ. Extracellular vesicles in cancer — implications for future improvements in cancer care. Nature Reviews Clinical Oncology. octubre de 2018;15(10):617-38.</p></td>
								</tr>
							  </table>

					</div>
				</div>



				<div class="ico-franja">
					<div class="ico-narrow-content">
						<div class="col-xs-offset-10">
								<h2><a href="m1u3.html" class="btn btn-primary btn-outline">siguiente unidad<br><font size="6"><span class="doradoActivo icon-arrow-circle-right"></span></font></a></h2>
						</div>


						</div>
					</div>



















		</div>
</div>



	<!-- jQuery -->
	<script src="js/jquery.min.js"></script>
	<!-- jQuery Easing -->
	<script src="js/jquery.easing.1.3.js"></script>
	<!-- Bootstrap -->
	<script src="js/bootstrap.min.js"></script>
	<!-- Carousel -->
	<script src="js/owl.carousel.min.js"></script>
	<!-- Stellar -->
	<script src="js/jquery.stellar.min.js"></script>
	<!-- Waypoints -->
	<script src="js/jquery.waypoints.min.js"></script>
	<!-- Counters -->
	<script src="js/jquery.countTo.js"></script>


	<!-- MAIN JS -->
	<script src="js/main.js"></script>

	</body>
</html>
